Zoetis is projected to report Q3 2026 revenue of $2.30 billion and adjusted EPS of $1.51, with the stock currently trading near $82.24 against a consensus price target of $86.70.
Investors are primarily focused on the performance of the U.S. Companion Animal segment, which analysts expect to decline 14.4% year-over-year to $915.20 million for the quarter.
This segment has faced significant headwinds from declining veterinary clinic visits and increased pet owner price sensitivity, which have pressured key franchises like Apoquel and the Librela pain portfolio. Analysts will closely watch for signs of market stabilization following management's recent full-year guidance cut and reports of intensifying competition.